Board Meeting To Be Held On May 23, 2018
to consider among other things, to approve the Audited Financial Results for the quarter and year ended 31st March, 2018 and related matters16-05-2018
16-05-2018
Natco Pharma: Tonic for growth
Natco's US portfolio is relatively insulated from price risks and faces limited competition06-05-2018
Reg 40(10) PCS Certificate
Please find enclosed herewith certificate under Clause 40 (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the half year ended 31st March, 2018.30-04-2018
Shareholding for the Period Ended March 31, 2018
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here10-04-2018
Compliance Certificate For The Half Year Ended 31St March 2018
Compliance certificate for the half year ended 31st March 201806-04-2018
Will new drug launch lift Natco Pharma?
Natco Pharma on Wednesday launched a generic version of Teriflunomide for the treatment of relapsing and remitting forms of multiple sclerosis (RRMS)04-04-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO launches 1st generic version of Oral tablets for Multiple Sclerosis in INDIA04-04-2018
Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0550 Name of the Signatory :- M AdinarayanaDesignation :- Company Secretary and Compliance Officer04-04-2018
Natco Pharma (786.8)
Investors with a short-term perspective can consider buying the stock of Natco Pharma at current levels. The stock encountered a key medium-term term resistance at around 1,050 in mid-January 201815-03-2018
Natco Pharma seeks USFDA nod for hepatitis drug
Natco Pharma Ltd has filed an abbreviated new drug application (ANDA) for Sofosbuvir tablets with the United States Food and Drug Administration (USFDA), according to a company release issued here01-03-2018